What should I do if I have hepatitis B-associated nephritis?
Aug 20, 2021
Source: Cainiu Health
Dr. Yuan Xiaoying
Introduction
Regarding treatment, the primary approach is to address the underlying disease. For hepatitis B, entecavir can be used for antiviral therapy, with a minimum duration of six months. For patients who do not achieve remission, corticosteroids and immunosuppressants may be added to the antiviral regimen to treat the associated kidney disease. A commonly employed therapeutic strategy involves low-dose corticosteroids combined with tacrolimus.
Hepatitis B virus–associated nephritis results from deposition of hepatitis B virus (HBV) in the kidneys, leading to renal injury. Clinically, it most commonly manifests as membranous nephropathy, followed by membranoproliferative glomerulonephritis.
Treatment begins with targeting the underlying disease—namely, chronic hepatitis B—using antiviral agents such as entecavir. Antiviral therapy should be continued for at least six months. In many cases, renal disease improves concurrently with HBV suppression; however, some patients may experience persistent nephropathy despite successful HBV control.
In such cases, corticosteroids and immunosuppressants may be added to antiviral therapy to manage the renal disease. A commonly used regimen involves low-dose corticosteroids combined with tacrolimus. Additionally, patients should adhere to a low-salt, low-fat, high-quality protein diet to minimize renal workload. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) may also be prescribed orally to reduce proteinuria and provide renoprotection, as part of symptomatic management.
